相似文献
1
Progress and problems when considering gene therapy for GSD-II.
Acta Myol. 2007 Jul;26(1):49-52.
2
Three patients with glycogen storage disease type II and the mutational spectrum of GAA in Korean patients.
Ann Clin Lab Sci. 2013 Summer;43(3):311-6.
3
Novel human pathological mutations. Gene symbol: GAA. Disease: glycogen storage disease 2.
Hum Genet. 2010 Apr;127(4):464.
4
Novel human pathological mutations. Gene symbol: GAA. Disease: glycogen storage disease 2.
Hum Genet. 2010 Apr;127(4):465.
5
Novel human pathological mutations. Gene symbol: GAA. Disease: glycogen storage disease 2.
Hum Genet. 2010 Apr;127(4):465.
6
Novel human pathological mutations. Gene symbol: GAA. Disease: glycogen storage disease 2.
Hum Genet. 2010 Apr;127(4):464.
7
Novel human pathological mutations. Gene symbol: GAA. Disease: glycogen storage disease 2.
Hum Genet. 2010 Apr;127(4):466.
8
Novel human pathological mutations. Gene symbol: GAA. Disease: glycogen storage disease 2.
Hum Genet. 2010 Apr;127(4):465.
9
An investigation of the possible influence of neutral alpha-glucosidases on the clinical heterogeneity of glycogenosis type II.
Ann Hum Genet. 1989 May;53(2):185-92. doi: 10.1111/j.1469-1809.1989.tb01783.x.
10
Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.
Mol Ther. 2005 Jan;11(1):57-65. doi: 10.1016/j.ymthe.2004.10.004.
引用本文的文献
1
Anti-EGF antibody cationic polymeric liposomes for delivery of the p53 gene for ovarian carcinoma therapy.
Int J Clin Exp Pathol. 2019 Jan 1;12(1):205-211. eCollection 2019.
2
Genetic counseling in Pompe disease.
Acta Myol. 2011 Dec;30(3):179-81.
3
Rhabdomyolysis: a review, with emphasis on the pediatric population.
Pediatr Nephrol. 2010 Jan;25(1):7-18. doi: 10.1007/s00467-009-1223-9.
4
Therapeutic approaches in glycogen storage disease type II/Pompe Disease.
Neurotherapeutics. 2008 Oct;5(4):569-78. doi: 10.1016/j.nurt.2008.08.009.
本文引用的文献
1
Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo.
Circ Res. 2006 Aug 18;99(4):e3-9. doi: 10.1161/01.RES.0000237661.18885.f6. Epub 2006 Jul 27.
2
Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.
J Pediatr. 2006 Jul;149(1):89-97. doi: 10.1016/j.jpeds.2006.02.035.
3
Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system.
Mol Ther. 2006 Oct;14(4):588-98. doi: 10.1016/j.ymthe.2006.03.024. Epub 2006 Jun 2.
4
Adenovirus: from foe to friend.
Rev Med Virol. 2006 May-Jun;16(3):167-86. doi: 10.1002/rmv.494.
5
Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice.
Mol Ther. 2006 Jan;13(1):127-34. doi: 10.1016/j.ymthe.2005.08.006. Epub 2005 Oct 5.
6
Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps.
J Virol. 2005 Aug;79(15):9933-44. doi: 10.1128/JVI.79.15.9933-9944.2005.
7
Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.
Mol Ther. 2005 Nov;12(5):876-84. doi: 10.1016/j.ymthe.2005.04.024. Epub 2005 Jul 6.
8
Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.
Mol Ther. 2005 Jun;11(6):889-98. doi: 10.1016/j.ymthe.2005.01.012.
9
Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver.
J Virol. 2005 Mar;79(6):3606-14. doi: 10.1128/JVI.79.6.3606-3614.2005.
10
Biology of adenovirus and its use as a vector for gene therapy.
Hum Gene Ther. 2004 Nov;15(11):1022-33. doi: 10.1089/hum.2004.15.1022.
Zotero 插件